Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

PRIMARY OBJECTIVES:

I. To determine the duration of response to metformin (metformin hydrochloride), carboplatin
and paclitaxel followed by maintenance with metformin as compared to the primary duration of
remission in within patient controls.

SECONDARY OBJECTIVES:

I. Determine the in situ effects of metformin on lethal-7 (let-7) expression as determined by
in situ hybridization. (Phase Ia) II. To determine the feasibility of using a core biopsy to
perform ribonucleic acid (RNA) sequencing. (Phase Ia) III. To determine epigenomic effects of
metformin via RNA-sequencing (Seq). (Phase Ia) IV. To determine the biologic effects of
metformin through evaluation of pre and post metformin tumor samples for phosphorylated (p)
adenosine monophosphate (AMP)-activated protein kinase (AMPK), v-myc myelocytomatosis viral
oncogene homolog (avian) (myc), mechanistic target of rapamycin (mTOR) and phosphorylated
v-akt Murine Thymoma Viral Oncogene Homolog 1 (pAKT). (Phase Ia) V. To assess safety and
tolerability of metformin and carboplatin and paclitaxel in patients with platinum sensitive
recurrent ovarian cancer. (Phase Ib)

OUTLINE:

Phase Ia: Patients receive metformin hydrochloride orally (PO) once daily (QD) on days 1-7
and twice daily (BID) on days 8-21.

Phase Ib: Patients receive metformin hydrochloride BID on days 1-21, paclitaxel intravenously
(IV) over 3 hours on day 1, and carboplatin IV over 30 minutes on day 1. Treatment repeats
every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 12 weeks.

Inclusion Criteria:

- Patients must have histologically or cytologically confirmed high grade serous
ovarian, fallopian tube or primary peritoneal cancer

- Patients must have measurable disease, defined as at least one lesion that can be
accurately measured in at least one dimension in accordance with Response Evaluation
Criteria in Solid Tumors (RECIST) criteria version (v.) 1.1; for those patients in the
Phase 1a portion that are agreeable, disease must be amenable to ultrasound or
computed tomography (CT) guided biopsy of a lesion outside of the target lesion;
patients must have histologically or cytologically confirmed high grade serous
ovarian, fallopian tube or primary peritoneal cancer

- No antineoplastic therapy (eg, drugs, biologicals, monoclonal antibodies, etc) or
radiotherapy within 6 months before enrollment; patients previously treated with
antineoplastic therapy in the past must have recovered (ie, grade =< 1 toxicity or
patient's baseline status, except alopecia) from all treatment-related toxicities

- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

- Absolute neutrophil count >= 1,500 cells/mm^3

- Platelets >= 100,000 cells/mm^3

- Hemoglobin >= 9 g/dL

- Total bilirubin =< 1.5 times the upper limit of normal

- Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) (serum glutamic
oxaloacetic transaminase [SGOT]/serum glutamate pyruvate transaminase [SGPT]) =< 2.5
times institutional normal limits

- Creatinine =< 1.5 for men and 1.4 for women

- Fasting blood sugar =< 126

- Hemoglobin A1C =< 6.5

- Patients in the Phase 1a portion of the clinical trial must have a tumor that is
deemed safe to biopsy and must consent to serial biopsies and or surgical resection
after treatment with metformin

- Patients must be minimally, status post bilateral salpingo-oophorectomy

- Ability to understand and willingness to sign a written informed consent and Health
Insurance Portability and Accountability Act (HIPAA) consent document

- Willing and able to comply with all appointments for treatment, lab testing, biopsies,
imaging and any other testing

- Suitable venous access for infusion of chemotherapy and phlebotomy

Exclusion Criteria:

- Patients may not be receiving any other investigational agents

- Patients must not have evidence of disease recurrence within 6 months of completing
the last dose of platinum based therapy

- Patient with current diagnosis of diabetes, or currently taking insulin, metformin,
sulfonylureas, or other medications used for the treatment of elevated blood sugar

- Conditions leading to increased risk of metformin induced lactic acidosis, including
congestive heart failure (New York Heart Association [NYHA] class III or IV), history
of acidosis, or daily intake of 3 or more alcoholic drinks

- Use of metformin in the past 6 months

- History of allergic reactions/hypersensitivity reactions to metformin

- History of allergic or hypersensitivity reaction to carboplatin, paclitaxel, or
Cremophor® EL

- Baseline nausea > grade 1

- Baseline evidence of metabolic acidosis, with total carbon dioxide (TCO2) of less than
20

- Patients with history of >= grade 2 neurotoxicity or any toxicity requiring
discontinuation from taxanes chemotherapy that is not resolved to =< grade 1

- Any condition that would prohibit patient from being able to take and digest
metformin, such as gastroparesis, history of malabsorption, history of baseline
diarrhea, current symptoms of small bowel obstruction, current symptoms of an ileus,
history of a resection of the stomach or small bowel, or history of Crohn's
disease/colitis

- Current alcohol abuse: patients using more than 1 standard unit of alcohol per day for
the past 30 days; a standard unit of alcohol is defined as a 12 oz beer (350 mL), 1.5
oz (45 mL) of 80-proof alcohol, or one 6-oz (175 mL) glass of wine

- Uncontrolled current illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- Pregnant or breast feeding

- Systemic infection requiring IV antibiotic therapy within 14 days preceding the first
dose of metformin, or other severe infection

- Diagnosis of or treated for another malignancy within 2 years of enrollment; patient
with non-melanoma skin cancer or carcinoma in situ of any type, are not excluded if
they have undergone complete resection; patients with a history of stage IA
endometrial endometrioid carcinomas are also not excluded

- Diagnosis of primary central nervous system (CNS) disease or carcinomatous meningitis

- Patient has symptomatic brain metastasis; if patient has asymptomatic brain
metastasis, must have:

- Stable brain metastasis for 2 years documented radiographically.

- Be without any neurological dysfunction that would confound evaluation of adverse
events

- Women of child-bearing potential (WOCBP) are not eligible for the study; since the
standard of care for ovarian cancer treatment is total abdominal hysterectomy and
bilateral salpingo-oophorectomy this is not thought to exclude patients who otherwise
might want to participate